Skip to main content

REVIEW article

Front. Cell Dev. Biol.

Sec. Cellular Biochemistry

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1527309

This article is part of the Research Topic Unraveling the Role of Protein Modifications in Tumor Dynamics and Immune Modulation View all articles

Tumor-promoting effect and tumor immunity of SRSFs

Provisionally accepted
Shuai Zhang Shuai Zhang 1Yongxi Zhang Yongxi Zhang 2Sijia Feng Sijia Feng 2Miaomiao Han Miaomiao Han 1Zixi Wang Zixi Wang 1Dan Qiao Dan Qiao 1Jiaqi Tian Jiaqi Tian 1Lan Wang Lan Wang 1Baoshun Du Baoshun Du 3Zheying Zhang Zheying Zhang 1*Jiateng Zhong Jiateng Zhong 1*
  • 1 Xinxiang Medical University, Xinxiang, China
  • 2 The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan Province, China
  • 3 Xinxiang Central Hospital, Xinxiang, Henan Province, China

The final, formatted version of the article will be published soon.

    serine/arginine-rich splicing factors (SRSFs) are a family of 12 RNA-binding proteins crucial for the precursor messenger RNA (pre-mRNA) splicing. SRSFs are involved in RNA metabolism events such as transcription, translation, and nonsense decay during the shuttle between the nucleus and cytoplasm, which are important components of genome diversity and cell viability. SRs recognize splicing elements on pre-mRNA and recruit the spliceosome to regulate splicing. In tumors, aberrant expression of SRSFs leads to aberrant splicing of RNA, affecting the proliferation, migration, and anti-apoptotic ability of tumor cells, highlighting the therapeutic potential of targeted SRSFs for the treatment of diseases. The body's immune system is closely related to the occurrence and development of tumor, and SRSFs can affect the function of immune cells in the tumor microenvironment by regulating the alternative splicing of tumor immune-related genes. we review the important role of SRSFs-induced aberrant gene expression in a variety of tumors and the immune system, and prospect the application of SRSFs in tumor. We hope that this review will inform future treatment of the disease.

    Keywords: Alternative splicing (AS), SRSF, pre-mRNA, tumor, immune

    Received: 13 Nov 2024; Accepted: 17 Feb 2025.

    Copyright: © 2025 Zhang, Zhang, Feng, Han, Wang, Qiao, Tian, Wang, Du, Zhang and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zheying Zhang, Xinxiang Medical University, Xinxiang, China
    Jiateng Zhong, Xinxiang Medical University, Xinxiang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more